Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of APSLXR in Meniere's Disease and Vertigo
NCT04674735Phase 1Withdrawn
- Sponsor
- Apsen Farmacêutica
- Start
- Jan 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of APSLXR in Meniere's disease (MD) and vertigo, sponsored by Apsen Farmacêutica. Primary endpoint: Incidence of Adverse Events at 60 days. Planned start Jan 2023; status: withdrawn.
02
Drugs
APSLXR
03
Conditions
Meniere's disease (MD)vertigo
Beyond the preview
Go deeper on NCT04674735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04674735.